Biomatrix's synovial fluid mimic approved
This article was originally published in Clinica
The FDA has approved Biomatrix' elastoviscous fluid Synvisc for treatment of osteoarthritis of the knee. As a result Biomatrix will receive a $12 million milestone payment from Wyeth-Ayerst Laboratories, which will market and distribute the product in the US.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.